TG Therapeutics (TG Therapeutics) Debt-to-Revenue : 0.63 (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is TG Therapeutics Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

TG Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.4 Mil. TG Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $109.3 Mil. TG Therapeutics's annualized Revenue for the quarter that ended in Dec. 2023 was $175.9 Mil. TG Therapeutics's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.63.

TG Therapeutics Debt-to-Revenue Historical Data

The historical data trend for TG Therapeutics's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TG Therapeutics Debt-to-Revenue Chart

TG Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

268.45

276.16

11.82

29.82

0.47

TG Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial															259.56	3.46	1.70	0.02	0.63

Competitive Comparison of TG Therapeutics's Debt-to-Revenue

For the Biotechnology subindustry, TG Therapeutics's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TG Therapeutics's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TG Therapeutics's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where TG Therapeutics's Debt-to-Revenue falls into.

TG Therapeutics Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

TG Therapeutics's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(1.446	+	109.349)	/	233.662
	=	0.47

TG Therapeutics's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(1.446	+	109.349)	/	175.884
	=	0.63

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.

TG Therapeutics Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of TG Therapeutics's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

TG Therapeutics (TG Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TG Therapeutics Inc (NAS:TGTX) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

NKB2:Germany NKB2:Germany

Address

3020 Carrington Mill boulevard, Suite 475, Morrisville, NC, USA, 27560

Website

https://www.tgtherapeutics.com

TG Therapeutics Inc is a fully-integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.

Executives

Laurence N Charney	director	MARVEL ENTERTAINMENT, INC., 417 FIFTH AVENUE, NEW YORK NY 10016
Sean A Power	officer: CFO, Secretary and Treasurer	787 SEVENTH AVENUE, 48TH FLOOR, NEW YORK NY 10019
Michael S Weiss	director, officer: CEO and President	750 LEXINGTON AVE, NEW YORK NY 10022
Sagar Lonial	director	C/O TG THERAPEUTICS, INC., 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NY 10014
Yann Echelard	director	C/O LFB BIOTECHNOLOGIES, S.A.S., 3, AVENUE DES TROPIQUES LES ULIS, COURTABOEUF I0 91958
Ra Capital Management, L.p.	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Kenneth Hoberman	director	750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10024
Daniel Hume	director	3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK NY 10019
William James Kennedy	director	C/O XTL BIOPHARMACEUTICALS LTD, 711 EXECUTIVE BLVD., SUITE Q, VALLEY COTTAGE NY 10989
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Lfb Biotechnologies S.a.s.u.	10 percent owner	3 AVENUE DES TROPIQUES, LES ULIS, COURTABOEUF I0 91958
Mark Schoenebaum	director	787 SEVENTH AVENUE, 48TH FLOOR, NEW YORK NY 10019
Opus Point Partners, Llc	10 percent owner	787 7TH AVENUE, 48TH FLOOR, NEW YORK NY 10019